| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 61 | Composition comprising probiotic bacteria for use in the treatment of immune disorders | US13583477 | 2011-03-07 | US08734783B2 | 2014-05-27 | Giovanni Mogna; Gian Paolo Strozzi; Luca Mogna; Lorenzo Drago |
| The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis. | ||||||
| 62 | PROBIOTIC FUNCTIONAL FOOD SUITABLE FOR IMMUNOCOMPROMISED INDIVIDUALS UNDERGOING TREATMENT SUCH AS CHEMOTHERAPY AND/OR RADIOTHERAPY | US13879611 | 2011-10-14 | US20140072541A1 | 2014-03-13 | Maria Loreto Ormeno Saavedra; Erica Castro Inostroza; Rodrigo Borquez Yanez; Margarita Gonzalez Riquelme; Rodrigo Vera Garcia; Natalia Toledo Aguilar |
| The invention relates to a probiotic functional food comprising: a biomass of Lactobacillus spp. strains conditioned to withstand temperatures of between −30 and −40° C., and cryoprotective agents. Said food comprises jellies, desserts, juices and/or milk derivatives, preferably ice cream. This functional food is intended for patients undergoing therapies such as chemotherapy and/or radiotherapy, since it counteracts the side effects of the cancer treatment. | ||||||
| 63 | LACTOBACILLUS SALIVARIUS AND METHOD FOR PREPARING METABOLITE THEREOF, COMPOSITION OF LACTOBACILLUS SALIVARIUS AND METABOLITE THEREOF AND USE OF THE COMPOSITION | US13982965 | 2012-01-17 | US20130309212A1 | 2013-11-21 | Ming Zhang; Fang Wang; Huiyuan Guo; Jun Zhu; Lu Jiang |
| Provided is a Lactobacillus salivarius belonging to Lactobacillus salivarius subsp. Salivarius and deposited in China General Microbiological Culture Collection Center with an accession number CGMCC No: 3606. Further provided is a method for preparing a metabolite of the Lactobacillus salivarius, wherein the Lactobacillus salivarius is as described above. Further provided is a composition, comprising viable strains of the Lactobacillus salivarius and/or the metabolite of the Lactobacillus salivarius prepared as described above. Further provided is a use of the composition in preparation of drugs for prevention and/or treatment of cancers and a method for treating and/or preventing cancers. The viable strains of Lactobacillus salivarius and the metabolite of Lactobacillus salivarius provided in the present invention can both remove the genotoxicity of 4-NQQ in vivo, thus exerting an effect of effectively preventing and/or treating cancers. | ||||||
| 64 | ANTI-INFLAMMATORY AND ANTI-VAGINITIS FOOD COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING LACTOBACILLUS | US13097995 | 2011-04-29 | US20110268715A1 | 2011-11-03 | Pei-Shan HSIEH; Yi-Chun Tsai; Albert Kuo; Yi-Chun Chen |
| An anti-inflammatory and anti-vaginitis food composition and/or pharmaceutical composition includes Lactobacillus salivarius subsp. salicinius AP-32 (CCTCC stock No. M2011127), Lactobacillus reuteri TE-33(CCTCC stock No. M2011126), Lactobacillus acidophilus F-1 (CCTCC stock No. M2011124), Lactobacillus rhamnosus CT-53 (CCTCC stock No. M2011129) or combinations thereof. The present invention may inhibit TNF-α secretion and promote IL-10 secretion of dendritic cells and therefore inhibit inflammation, particularly inflammation of vagina mucosa cells. The present invention may be presented as oral probiotics and direct-use vagina probiotics. | ||||||
| 65 | Process and composition for the manufacture of a microbial-based product | US12822933 | 2010-06-24 | US07858336B1 | 2010-12-28 | Matthew Ryan Garner; Joseph Flint |
| Processes to produce microorganisms that can be incorporated into a microbial-based product that results in high viable cell yields and shelf-stable products are disclosed. These microbial-based products are useful for inhibiting pathogenic growth and as a food additive. A preferred microorganism is the lactic acid producing bacteria, Lactobacillus amylovorus M35. In one embodiment, the process comprises inoculating a lactobacillus fermentation medium with M35 cells, harvesting the M35 cells at mid to late log phase, concentrating the M35 cells, and preserving the M35 cells at a concentration of at least 5×109 cfu/ml. | ||||||
| 66 | Probiotic lactobacillus salivarius strains | US10205318 | 2002-07-26 | US20030091549A1 | 2003-05-15 | John Kevin Collins; Gerald Christopher O'Sullivan; Liam O'Mahony; Fergus Shanahan; Barry Kiely |
| A Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome. | ||||||
| 67 | LACTOBACILLUS SALIVARIUS CJLS1511, ANIMAL FEED ADDITIVE COMPOSITION COMPRISING SAME BACTERIUM OR DEAD CELLS THEREOF, AND METHOD FOR PRODUCING SAME DEAD CELLS | US16324462 | 2017-08-07 | US20190216867A1 | 2019-07-18 | Ji Eun KIM; Kyeong Su CHAE; Sung Hun KIM; Seok Woo CHEE; Joong Su LEE |
| The present invention relates to Lactobacillus salivarius CJLS1511, a composition for animal feed additives comprising the same or its inactivated bacterial cells, and a method for preparing the inactivated bacterial cells. | ||||||
| 68 | PROCESS FOR THE MANUFACTURE OF PATHOGEN INHIBITING BACTERIA | US15905557 | 2018-02-26 | US20180243354A1 | 2018-08-30 | Matthew Ryan GARNER; Joseph F. Flint |
| Processes to produce microorganisms that can be incorporated into a microbial-based product that results in high viable cell yields and shelf-stable products are disclosed. These microbial-based products are useful for inhibiting pathogenic growth and as a food additive. A preferred microorganism is a lactic acid producing bacteria. In one embodiment, the process comprises inoculating either a fermentation medium with enterococcus or pediococcus bacterial cells, harvesting the enterococcus or pediococcus bacterial cells at least partially during the log phases, concentrating the bacterial cells, and preserving the bacterial cells at a concentration of at least 5×109 cfu/ml. | ||||||
| 69 | LACTOBACILLI FOR TREATING CARDIAC DYSFUNCTION | US15744252 | 2016-07-07 | US20180207210A1 | 2018-07-26 | Lotta Stenman; Sampo Lahtinen; John Konhilas |
| The use of a bacterium of the species Lactobacillus salivarius in the manufacture of a food product, dietary supplement or medicament for treating cardiac dysfunction, particularly myocardial infarction, congestive heart failure, dilated cardiomyopathy or inflammatory heart disease (including endocarditis, inflammatory cardiomegaly and myocarditis) is disclosed. | ||||||
| 70 | BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS | US15927986 | 2018-03-21 | US20180207209A1 | 2018-07-26 | REMY BURCELIN; DIDIER CARCANO; SAMPO LAHTINEN; LOTTA STENMAN; JOHN KONHILAS |
| This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure. | ||||||
| 71 | PROCESS FOR THE MANUFACTURE OF PATHOGEN INHIBITING BACTERIA | US15686971 | 2017-08-25 | US20170348364A1 | 2017-12-07 | Matthew Ryan GARNER; Joseph F. Flint |
| Processes to produce microorganisms that can be incorporated into a microbial-based product that results in high viable cell yields and shelf-stable products are disclosed. These microbial-based products are useful for inhibiting pathogenic growth and as a food additive. A preferred microorganism is a lactic acid producing bacteria. In one embodiment, the process comprises inoculating a lactobacillus fermentation medium with lactic acid producing bacterial cells, harvesting the lactic acid producing bacterial cells at least partially during the log phases, concentrating the lactic acid producing bacterial cells, and preserving the lactic acid producing bacterial cells at a concentration of at least 5×109 cfu/ml. | ||||||
| 72 | ANITMICROBIAL PEPTIDE PRODUCED BY INTESTINAL LACTOBACILLUS SALIVARIUS | US15477544 | 2017-04-03 | US20170253638A1 | 2017-09-07 | Paul ROSS; Eileen O'SHEA; Colin HILL |
| An antimicrobial peptide having potent antibacterial activity against Listeria monocytogenes and Staphylococcus aureus is described. Also described is an isolated Lactobacillus salivarius DPC6502 strain as deposited with the National Collection of Industrial and Marine Bacteria under the Accession No. NCIMB 41840, and variants thereof, wherein the isolated bacteria and variants thereof express an antimicrobial peptide of the invention. | ||||||
| 73 | Fermented infant formula with non digestible oligosaccharides | US15441405 | 2017-02-24 | US09717270B2 | 2017-08-01 | Thomas Ludwig; Sylvie Huybers; Evan Abrahamse; Houkje Bouritius |
| The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation. | ||||||
| 74 | FERMENTED INFANT FORMULA WITH NON DIGESTIBLE OLIGOSACCHARIDES | US15441405 | 2017-02-24 | US20170156389A1 | 2017-06-08 | Thomas LUDWIG; Sylvie HUYBERS; Evan ABRAHAMSE; Houkje BOURITIUS |
| The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation. | ||||||
| 75 | Composition comprising probiotic bacteria for use in the treatment of immune disorders | US14286308 | 2014-05-23 | US09498503B2 | 2016-11-22 | Giovanni Mogna; Gian Paolo Strozzi; Luca Mogna; Lorenzo Drago |
| The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis. | ||||||
| 76 | Compositions | US14129851 | 2012-06-30 | US09308271B2 | 2016-04-12 | Birgitte Yde |
| The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 109 to 1013 cfu/g of the composition of lactic acid bacteria cells, wherein the composition is characterized by that it also comprises following amounts of protective agents (all amounts of protective agents below are given relative to 1 g of lactic acid bacteria cells in the composition): from 6 to 9 g of trehalose, from 0.1 to 1 g of inulin and from 0.5 to 3 g of hydrolyzed casein, and by that it does not comprise a salt of alginic acid. The composition has an improved storage stability of the cell of interest. Comparison experiments have been made between compositions with and without alginate and it has been found that there is substantially no difference between compositions with or without alginate with regard to stability. Further, the invention relates to a method for preparing a dry lactic acid bacteria composition. | ||||||
| 77 | Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing Lactobacillus | US13097995 | 2011-04-29 | US09011839B2 | 2015-04-21 | Pei-Shan Hsieh; Yi-Chun Tsai; Albert Kuo; Yi-Chun Chen |
| An anti-inflammatory and anti-vaginitis food composition and/or pharmaceutical composition includes Lactobacillus salivarius subsp. salicinius AP-32 (CCTCC stock No. M2011127), Lactobacillus reuteri TE-33 (CCTCC stock No. M2011126), Lactobacillus acidophilus F-1 (CCTCC stock No. M2011124), Lactobacillus rhamnosus CT-53 (CCTCC stock No. M2011129) or combinations thereof. The present invention may inhibit TNF-α secretion and promote IL-10 secretion of dendritic cells and therefore inhibit inflammation, particularly inflammation of vagina mucosa cells. The present invention may be presented as oral probiotics and direct-use vagina probiotics. | ||||||
| 78 | NOVEL COMPOSITIONS | US14129851 | 2012-06-30 | US20140255366A1 | 2014-09-11 | Birgitte Yde |
| The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 109 to 1013 cfu/g of the composition of lactic acid bacteria cells, wherein the composition is characterized by that it also comprises following amounts of protective agents (all amounts of protective agents below are given relative to 1 g of lactic acid bacteria cells in the composition): from 6 to 9 g of trehalose, from 0.1 to 1 g of inulin and from 0.5 to 3 g of hydrolyzed casein, and by that it does not comprise a salt of alginic acid. The composition has an improved storage stability of the cell of interest. Comparison experiments have been made between compositions with and without alginate and it has been found that there is substantially no difference between compositions with or without alginate with regard to stability. Further, the invention relates to a method for preparing a dry lactic acid bacteria composition. | ||||||
| 79 | Fermented Foodstuff | US13876386 | 2011-09-29 | US20130259844A1 | 2013-10-03 | Peter Brooks; Jane Beal; Soumela Savvidou; Vlasta Demeckova |
| A fermented foodstuff composition for human consumption is provided, the foodstuff composition being prepared by the fermentation of a foodstuff substrate with a lactic acid producing bacteria, the lactic acid bacteria being characterised by: a) being viable under the conditions prevailing in the human gastrointestinal tract; b) being a bacteria capable of aggregating and/or coaggregating with one or more pathogens; and c) being able to produce upon fermentation in the foodstuff substrate lactic acid in an amount of at least a minimum inhibitory concentration of lactic acid. | ||||||
| 80 | COMPOSITION COMPRISING PROBIOTIC BACTERIA FOR USE IN THE TREATMENT OF IMMUNE DISORDERS | US13583477 | 2011-03-07 | US20130149342A1 | 2013-06-13 | Giovanni Mogna; Gian Paolo Strozzi; Luca Mogna; Lorenzo Drago |
| The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis. | ||||||
QQ群二维码
意见反馈
意见反馈